Fierce Pharma March 4, 2024
Zoey Becker

After the U.S. government last month floated its first offers for 10 drugs on Medicare as part of the negotiations process laid out in the Inflation Reduction Act (IRA), the pricing talks are now in full swing.

Every drugmaker with a product on the list has responded to the government’s Feb. 1 pricing offer with a counteroffer, the Department of Health and Human Services (HHS) said in a Monday press release.

The agency is pleased with the “good-faith, up front negotiations,” HHS Secretary Xavier Becerra said in the release. “We are committed to constructive dialogue and are glad the drug companies are coming to the table.”

The industry, for its part, has routinely voiced complaints about a “lack of transparency”...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, CMS, Govt Agencies, HHS, Insurance, Medicare, Pharma, Pharma / Biotech
How our genome is like a generative AI model
Can Pfizer, Sangamo energise haemophilia A gene therapy?
Contributed Content: 2 Alternatives to Ineffective Prescription Drug Rebates
Pharma Pulse 7/25/24: Driving CAR-Ts for Treatment in Cancer and Immunology, CrowdStrike Explains What Went Wrong in Global Outage & more
Roche says it’ll move quickly with ‘differentiated’ obesity drugs

Share This Article